GSK-3β disrupts neural oscillatory function to inhibit learning and memory in rats

Abstract

Background. Alterations in glycogen synthase kinase-3β (GSK-3β) activity have been implicated in disorders of cognitive impairment including Alzheimer’s disease and schizophrenia. Another characteristic of cognitive impairment is the dysregulation of neural oscillatory activity, macroscopic electrical rhythms in brain critical to systems communication. A direct functional relationship between GSK-3β and neural oscillations has not been elucidated.Methods. In the present study, the impact of increasing GSK-3β activity in prefrontal cortex (PFC) or hippocampus (HIP) on the regulation of neural oscillations in rats was investigated using an adeno-associated viral vector containing a persistently active mutant of GSK-3β (S9A), and changes in learning and memory and tau phosphorylation assessed.Results. Increasing GSK-3β activity in either region had similar effects on oscillatory spectral power, enhancing theta and/or gamma oscillatory power recorded from one or both regions. Increasing PFC GSK-3β activity additionally suppressed high gamma PFC-HIP coherence. These oscillatory changes were accompanied by deficits in recognition memory, spatial learning and/or reversal learning. Increased pathogenic tau phosphorylation was also evident in regions where GSK-3β activity was elevated. Conclusions. These findings indicate that increased GSK-3β activity in PFC or HIP dysregulates neural oscillatory function in, and between, these regions. This suggests that GSK-3β may not only play an early role in cognitive decline in Alzheimer’s disease but may also play a more central role in disorders of cognitive dysfunction through the regulation of neurophysiological network function.